{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:02:04Z","timestamp":1791216124200,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,11]]},"DOI":"10.7759\/cureus.103428","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:23:16Z","timestamp":1770834196000},"source":"Crossref","is-referenced-by-count":1,"title":["Breast Cancer Metastasis with a Ureteral Obstruction and Bladder Mass"],"prefix":"10.7759","author":[{"given":"Sasha","family":"Mainer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lachmayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lemon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wylly","family":"Killorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"American Cancer Society. Breast cancer facts & figures 2024-2025. (2024). Accessed: November 18, 2025: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/20...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease","volume":"358","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2001","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001, 358:1389-99. 10.1016\/S0140-6736(01)06524-2","journal-title":"Lancet"},{"key":"ref3","unstructured":"National Cancer Institute. cancer stat facts: female breast cancer. (2025). Accessed: November 18, 2025: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184680","article-title":"New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes","volume":"12","author":"Buonomo OC","year":"2017","unstructured":"Buonomo OC, Caredda E, Portarena I, et al.. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS One. 2017, 12:e0184680. 10.1371\/journal.pone.0184680","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study","volume":"8","author":"Wu Q","year":"2017","unstructured":"Wu Q, Li J, Zhu S, et al.. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017, 8:27990-6. 10.18632\/oncotarget.15856","journal-title":"Oncotarget"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7408","article-title":"Bladder metastasis from breast cancer: a systematic review","volume":"12","author":"Karjol U","year":"2020","unstructured":"Karjol U, Jonnada P, Cherukuru S, Chandranath A. Bladder metastasis from breast cancer: a systematic review. Cureus. 2020, 12:e7408. 10.7759\/cureus.7408","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976947","article-title":"From women to women-hematuria during therapy for metastatic breast cancer, what to suspect and when to be alarmed; bladder metastasis from breast cancer-our experience and a systematic literature review","volume":"12","author":"Malinaric R","year":"2022","unstructured":"Malinaric R, Balzarini F, Granelli G, et al.. From women to women-hematuria during therapy for metastatic breast cancer, what to suspect and when to be alarmed; bladder metastasis from breast cancer-our experience and a systematic literature review. Front Oncol. 2022, 12:976947. 10.3389\/fonc.2022.976947","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14382","article-title":"Metastasis to the bladder from primary breast cancer: a case report and literature review","volume":"27","author":"Zhou H","year":"2024","unstructured":"Zhou H, Liu D, Chen L, et al.. Metastasis to the bladder from primary breast cancer: a case report and literature review. Oncol Lett. 2024, 27:249. 10.3892\/ol.2024.14382","journal-title":"Oncol Lett"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4968-7","article-title":"Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database","volume":"173","author":"Chang E","year":"2019","unstructured":"Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Res Treat. 2019, 173:209-16. 10.1007\/s10549-018-4968-7","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103730","article-title":"Survival outcomes for women with a solitary extracranial metastasis from breast cancer","volume":"75","author":"Dyer P","year":"2024","unstructured":"Dyer P, Xie J, Tran PK, Byrne K. Survival outcomes for women with a solitary extracranial metastasis from breast cancer. Breast. 2024, 75:103730. 10.1016\/j.breast.2024.103730","journal-title":"Breast"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102114","article-title":"Prognostic factors in patients with oligometastatic breast cancer - a systematic review","volume":"91","author":"van Ommen-Nijhof A","year":"2020","unstructured":"van Ommen-Nijhof A, Steenbruggen TG, Schats W, et al.. Prognostic factors in patients with oligometastatic breast cancer - a systematic review. Cancer Treat Rev. 2020, 91:102114. 10.1016\/j.ctrv.2020.102114","journal-title":"Cancer Treat Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors","volume":"38","author":"Miettinen M","year":"2014","unstructured":"Miettinen M, McCue PA, Sarlomo-Rikala M, et al.. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014, 38:13-22. 10.1097\/PAS.0b013e3182a0218f","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP5UAFMSA9ZQBZ","article-title":"Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas","volume":"138","author":"Liu H","year":"2012","unstructured":"Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012, 138:57-64. 10.1309\/AJCP5UAFMSA9ZQBZ","journal-title":"Am J Clin Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000922","article-title":"Immunohistochemical differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma involvement of the bladder","volume":"41","author":"Borhan WM","year":"2017","unstructured":"Borhan WM, Cimino-Mathews AM, Montgomery EA, Epstein JI. Immunohistochemical differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma involvement of the bladder. Am J Surg Pathol. 2017, 41:1570-5. 10.1097\/PAS.0000000000000922","journal-title":"Am J Surg Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin MB","year":"2014","unstructured":"Amin MB, Trpkov K, Lopez-Beltran A, Grignon D. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014, 38:e20-34. 10.1097\/PAS.0000000000000240","journal-title":"Am J Surg Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105016","article-title":"Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis","volume":"217","author":"Nakatani S","year":"2026","unstructured":"Nakatani S, Hayashi T, Hosaka A, Maeda H. Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2026, 217:105016. 10.1016\/j.critrevonc.2025.105016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35101","article-title":"HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: Implications in treatment and prognosis","volume":"130","author":"Lin M","year":"2024","unstructured":"Lin M, Luo T, Jin Y, et al.. HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: Implications in treatment and prognosis. Cancer. 2024, 130:851-62. 10.1002\/cncr.35101","journal-title":"Cancer"},{"key":"ref18","unstructured":"Orange Book. approved drug products with therapeutic equivalence evaluations. (2026). Accessed: February 7, 2026: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, et al.. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016, 196:1021-9. 10.1016\/j.juro.2016.06.049","journal-title":"J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435765-breast-cancer-metastasis-with-a-ureteral-obstruction-and-bladder-mass","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:23:17Z","timestamp":1770834197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435765-breast-cancer-metastasis-with-a-ureteral-obstruction-and-bladder-mass"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.103428","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}